TrialThe Lancet. Oncology2025

Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.

Hee Kyung Ahn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.